Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.31 |
| ▸ | GSR | P00390 | 1/20 | 0.30 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9028993 | 0.84 | ALDH1A1 (0.35) | ALDH1A1MAPTKDM4EUSP2 | |
| SCHEMBL9028187 | 0.84 | CA1 (0.36) | CA1CA2ALDH1A1MAPTKDM4E | |
| SCHEMBL6767062 | 0.81 | CA1 (0.33) | CA1CA2ALDH1A1MAPTKDM4E | |
| SCHEMBL6768799 | 0.81 | SMN1; SMN2 (0.34) | CA1CA2ALDH1A1MAPTKDM4E | |
| SCHEMBL6764086 | 0.81 | CA1 (0.33) | CA1CA2MAPTGABRA1GABRB1 | |
| SCHEMBL11706956 | 0.78 | USP2 (0.36) | CA1CA2ALDH1A1MAPTKDM4E | |
| SCHEMBL6766966 | 0.76 | ALDH1A1 (0.33) | ALDH1A1MAPTKDM4E | |
| SCHEMBL11706776 | 0.75 | USP2 (0.37) | CA1CA2ALDH1A1MAPTKDM4E | |
| SCHEMBL4466859 | 0.74 | USP2 (0.38) | CA1CA2ALDH1A1MAPTKDM4E | |
| SCHEMBL10394837 | 0.74 | CYP3A4 (0.45) | CA1CA2ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2121975-A | — | — | None | — | — | JP | disclosed |
| US-6686389-B2 | KIDNEY DISEASE, ORGAN TRANSPLANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-02-03 | — | — | US | disclosed |
| US-20020156296-A1 | 2,3-dihydrobenzofuran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-10-24 | — | — | US | disclosed |
| US-6403639-B1 | POTENT CYTOPROTECTIVE AGENT WHICH INHIBITS LIPID-PEROXIDATION FOR PREVENTION AND TREATMENT OF VARIOUS RENAL DISEASES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-0995437-A1 | 2,3-DIHYDROBENZOFURAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-04-26 | — | — | EP | disclosed |
| JP-H02121975-A | 2,3-DIHYDROBENZOFURAN DERIVATIVE | EISAI CO LTD | 1990-05-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156296-A1 | 2,3-dihydrobenzofuran derivatives | CBR1, CYP2F1, NDUFAF2 | CA1 2676/4885CA2 1997/4885ALDH1A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.